Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,898 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C. Lofters WS, et al. Among authors: wilson k. J Clin Oncol. 1997 Aug;15(8):2966-73. doi: 10.1200/JCO.1997.15.8.2966. J Clin Oncol. 1997. PMID: 9256141 Clinical Trial.
Effect of daily etidronate on the osteolysis of multiple myeloma.
Belch AR, Bergsagel DE, Wilson K, O'Reilly S, Wilson J, Sutton D, Pater J, Johnston D, Zee B. Belch AR, et al. Among authors: wilson j, wilson k. J Clin Oncol. 1991 Aug;9(8):1397-402. doi: 10.1200/JCO.1991.9.8.1397. J Clin Oncol. 1991. PMID: 1712835 Clinical Trial.
A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy.
Rusthoven J, Pater J, Kaizer L, Wilson K, Osoba D, Latreille J, Findlay B, Lofters WS, Warr D, Laberge F, et al. Rusthoven J, et al. Among authors: wilson k. Ann Oncol. 1991 Oct;2(9):681-6. doi: 10.1093/oxfordjournals.annonc.a058049. Ann Oncol. 1991. PMID: 1742224 Free article. Clinical Trial.
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Pater JL, Lofters WS, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C. Pater JL, et al. Among authors: wilson k. Ann Oncol. 1997 Feb;8(2):181-5. doi: 10.1023/a:1008247830641. Ann Oncol. 1997. PMID: 9093728 Free article. Clinical Trial.
5,898 results